cbcaaaeb

Mike Benson

Contact us by Email

Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.

More From Mike Benson

  • uploads///Article
    Company & Industry Overviews

    How Did AstraZeneca’s CVMD Franchise Perform in 2014?

    In 2014, AstraZeneca’s CVMD franchise generated nearly $9.8 billion, a 11% rise in sales as compared to $8.8 billion in 2013.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Merck & Co.’s Animal Health Segment

    The revenues of Merck & Co.’s Animal Health segment have improved due to increased sales in the Companion Animal Products segment.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Major Developments for Johnson & Johnson in 3Q16

    Major developments As discussed previously in this series, Johnson & Johnson’s (JNJ) 3Q16 performance was positive across all of its segments. However, the Consumer segment reported a decline in revenue, as the negative impact of foreign exchange more than offset operational growth. There were several major developments for JNJ during 3Q16. Pharmaceuticals segment In 3Q16, the […]

    By Mike Benson
  • uploads///Pharma
    Earnings Report

    Johnson & Johnson’s Pharmaceuticals Segment Grows in 2Q15

    Johnson & Johnson’s (JNJ) Pharmaceuticals segment grew by 1.0% at constant exchange rates, reporting a revenue of $7,946 million for 2Q15 over 2Q14.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Eli Lilly’s 1Q18 Earnings by Segment

    Eli Lilly’s (LLY) products are classified into two business segments: Human Pharmaceutical Products and Animal Health Products.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What Analysts Recommend for Novartis in March 2018

    As discussed earlier, Novartis (NVS) reported EPS (earnings per share) of $1.21 on revenues of $12.9 billion during 4Q17.

    By Mike Benson
  • uploads///Chart  NMDA
    Company & Industry Overviews

    What Are Sage Therapeutics’ Receptor-Based Products?

    Sage Therapeutics (SAGE) is focused on the development of the products for the treatment of life-threatening central nervous system (or CNS) disorders.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at Johnson & Johnson’s Post-2Q17 Valuation

    Headquartered in New Jersey, Johnson & Johnson (JNJ) is one of the largest pharmaceutical companies, with its products sold in over 200 countries worldwide. This series will look at how it has performed since its 2Q17 earnings announcement.

    By Mike Benson
  • uploads///Article
    Company & Industry Overviews

    Lilly’s Total Returns Are Lower than Some Pharma ETFs

    The total return for Lilly’s share price on the NYSE from July 2010 to June 2015 has been around 17.9%. This is lower than a few of the pharmaceutical ETFs.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    A Look at Ionis’s Revenue Streams in the Second Quarter

    Ionis Pharmaceuticals (IONS) reported year-over-year (or YoY) growth of 5% in revenues to $118 million during Q2 2018 as compared to the revenues of $112 million during the second quarter of 2017.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Johnson & Johnson’s Valuation Cheat Sheet

    On January 26, 2017, the company was trading at a forward PE of ~15.8x. Based on the last five years’ multiple range, JNJ’s current valuation is neither high nor low.

    By Mike Benson
  • uploads///Article
    Company & Industry Overviews

    Sanofi Increased Net Revenues in 2014

    Sanofi’s net revenues increased by ~2.5% to 33.8 billion euros in 2014, as compared to $23.2 billion in 2013.

    By Mike Benson
  • uploads///Article
    Earnings Report

    Novartis’s Adjusted Earnings per Share Declined 7% in 2Q15

    Novartis (NVS) posted its 2Q15 earnings on July 21, 2015. The company achieved adjusted EPS of $1.27 for 2Q15, ~7% lower than in 2Q14.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Analysts’ Estimates and Ratings for Novartis in October

    Novartis’s revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What Analysts Project for Eli Lilly in 3Q17

    For 3Q17, analysts estimate that Eli Lilly will post EPS of $1.03 on revenues of $5.5 billion.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Why the Majority of Analysts Deem Novartis a ‘Buy’

    Novartis met Wall Street analysts’ estimates for EPS (earnings per share) in 4Q16, reporting EPS of $1.12 as estimated but missing revenue estimates.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Analysts’ Recommendations for Merck & Co. after 4Q17

    Merck & Co. (MRK) missed Wall Street analysts’ estimates for revenues but surpassed analysts’ estimates earnings per share.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What Does Johnson & Johnson Predict for Its Medical Devices Segment?

    Johnson & Johnson’s (JNJ) medical devices segment deals with vision care, cardiovascular care, specialty surgery, orthopedics, surgical care, and diabetes care.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What Did AGN’s US Medical Aesthetics Segment Contribute in 1Q16?

    Allergan’s US medical aesthetics segment includes facial aesthetics, medical dermatology products, and a wide range of silicone and saline breast implants.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Merck’s Valuation Cheat Sheet for Fiscal 1Q16

    Merck & Co.’s (MRK) current valuation is neither high nor low. Its valuation multiple has followed the industry’s overall trend over the last five years.

    By Mike Benson
  • uploads///ccdafbcfbddefdffcb
    Company & Industry Overviews

    Market Response to EMA Validation of Opdivo Application

    BMY has four key oncology products, including Erbitux, Opdivo, Sprycel, and Yervoy. Two of these contributed more than $1 billion in 2014.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    GlaxoSmithKline’s Quarterly Revenue Trend in 4Q17

    GlaxoSmithKline (GSK) reported revenues of 7.64 billion pounds in 4Q17, a ~1% growth compared to 7.59 billion pounds in 4Q16.

    By Mike Benson
  • uploads///close up _
    Earnings Report

    Pfizer Missed Analysts’ Third-Quarter Revenue Estimates

    Pfizer (PFE) released its third-quarter earnings on October 30.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Understanding the Revenue Fall in AstraZeneca’s Largest Segment in 3Q16

    AstraZeneca’s (AZN) CVMD (Cardiovascular and Metabolic Disease) segment contributed nearly 32.4% of total company revenues in 3Q16.

    By Mike Benson
  • uploads///Costs
    Earnings Report

    Bristol-Myers Squibb’s Profitability and Financial Guidance

    Bristol-Myers Squibb estimates that its revenues will be between $15.5 billion and $15.9 billion, which is nearly flat as compared to 2014 revenues of $15.9 billion.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Merck’s Gardasil and What It Could Mean

    Total sales from Merck’s Gardasil during 3Q16 reached $860 million, a rise of ~38% over the $625 million in 3Q15.

    By Mike Benson
  • uploads///syringe _
    Company & Industry Overviews

    Assessing Novartis’s Performance in October So Far

    Novartis’s ADR (American depositary receipt) has fallen ~1.0% to date in October, while it’s risen nearly 3.3% in the last month.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    A Look at Incyte’s Valuation as of May 25

    Incyte reported EPS of -$0.19 on revenue of $382.3 million in Q1 2018 compared to revenue of $384.1 million in Q1 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Decoding Humana’s Revenue Stream in 2015

    Humana reported revenues of about $54.3 billion in its 2015 results. This amounts to a 12% revenue growth in 2015, compared to ~$48.1 billion in 2014.

    By Mike Benson
  • uploads///Chart  CELG
    Company & Industry Overviews

    Celgene Stock Performance in 1Q18

    Wall Street analysts estimate that Celgene (CELG) stock has the potential to return 31.6% over the next 12 months.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca and Its Oncology Segment’s Growth in 2Q16

    AstraZeneca’s (AZN) oncology segment is another key focus area. The segment’s contribution increased to more than 15% in 2Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What’s to Be Expected from Novartis’s 3Q16 Earnings?

    Novartis, one of the world’s largest pharmaceutical companies by revenue, is set to release its 3Q16 earnings on October 25, 2016.

    By Mike Benson
  • uploads///Growth
    Earnings Report

    Johnson & Johnson’s 3Q15 Changes in Growth Rate

    Foreign exchange rates seem to have had a negative impact on Johnson & Johnson’s growth rate since ~50% of total revenues are reported from sales outside the US.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What Analysts Think about Ionis

    In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What to Expect from Pfizer’s 2Q16 Earnings

    In Pfizer’s 2Q16 results, analysts expect to see EPS (or earnings-per-share) of $0.62 and revenues of ~$13.0 billion for 2Q16. The company has surpassed Wall Street analysts’ estimates for EPS over the last few quarters.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Mylan’s Recent Commercial and Product Developments

    Mylan’s recent commercial developments include the acquisition of the Cold-EEZE brand from ProPhase Labs and the acquisition of Meda AB.

    By Mike Benson
  • uploads///freestocks org  unsplash
    Company & Industry Overviews

    Merck and AstraZeneca Announced EMA Approval for Lynparza

    Lynparza (olaparib) is a poly(ADP-ribose) polymerase inhibitor, or PARP inhibitor, and part of Merck & Co. (MRK) and AstraZeneca’s (AZN) global strategic oncology collaboration.

    By Mike Benson
  • uploads///Neuroscience
    Earnings Report

    Bristol-Myers Squibb’s Neuroscience and Immunoscience Segments

    Sales for Bristol-Myers Squibb’s (BMY) neuroscience segment declined over 80% in 2Q15, while the immunoscience segment’s sales improved ~15% in 2Q15 as compared to 2Q14.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Understanding Bristol-Myers Squibb’s Other Segments

    Sales from Bristol-Myers Squibb’s Neuroscience segment declined by 94% in 1Q16. Sales from the Immunoscience segment improved by ~18.7% in 1Q16 over 1Q15.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    How Analysts Rate Bristol-Myers Squibb in 1Q18

    Wall Street analysts estimate Bristol-Myers Squibb’s top line to rise 6.5% to ~$5.2 billion in 1Q18.

    By Mike Benson
  • uploads///Chart  GSK
    Company & Industry Overviews

    How GlaxoSmithKline Stock Performed in 1Q18

    GlaxoSmithKline stock has risen ~6.4% in 1Q18, while its stock has risen ~12.6% YTD (year-to-date) as of April 6, 2018.

    By Mike Benson
  • uploads///pina messina  unsplash
    Company & Industry Overviews

    Eli Lilly’s Valuation on May 17

    On May 17, Eli Lilly was trading at a forward PE multiple of 15.2x, which compares to the industry average of 13.6x.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    GlaxoSmithKline Increases Top Line in 2Q16

    GlaxoSmithKline (GSK) reported a 10.9% increase in its top line in its 2Q16 earnings on July 27, 2016. It met Wall Street analysts’ estimates for revenues and EPS.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Analyzing Johnson & Johnson’s 1Q18 Profitability

    Johnson & Johnson (JNJ) reported revenues of $20.0 billion during 1Q18, 12.6% growth as compared to revenues of $17.8 billion during 1Q17.

    By Mike Benson
  • uploads///Chart  GILD
    Company & Industry Overviews

    Gilead Sciences Stock Performance in 1Q18

    Wall Street analysts estimate that Gilead Sciences (GILD) stock has the potential to return 21.1% over the next 12 months.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca’s Valuation Report Card: How Did It Score?

    The fundamental factors affecting stock prices and valuation include the performance of growth platforms as well as the exclusivity of blockbuster drugs.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca Is Taking Steps to Improve Its Position in Oncology

    During the last quarter, the oncology segment’s contribution to AstraZeneca (AZN) increased to over 15%. AZN’s key products for oncology are Zoladex, Faslodex, Iressa, and the new drug Tagrisso.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    European Medicines Agency Validates Merck’s Keytruda Combo

    Merck’s (MRK) Keytruda (pembrolizumab) is approved to treat various forms of cancer.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    MedMen’s Must-Know Revenue Drivers

    MedMen’s (MMNFF) reported revenues are generated from direct sales through its retail stores. The company has reported no material revenues from cultivation or production wholesale operations.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Did Bristol-Myers Squibb’s Other Segments Perform in 3Q16?

    Bristol-Myers Squibb’s (BMY) neuroscience segment sales fell over 37% in 3Q16, while the immunoscience segment sales rose ~18% in 3Q16 as compared to 3Q15.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Eli Lilly’s 1Q18 Earnings: Neuroscience Products Portfolio

    Cymbalta, an antidepressant drug, reported revenues of $169.6 million in 1Q18, a 3% growth compared to $174.6 million in 1Q17.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Novartis Will Report Its 4Q15 Earnings on January 27

    Novartis is set to release its 4Q15 and full-year 2015 earnings on January 27, 2016. Analysts estimate an EPS of $1.32 for 4Q15.

    By Mike Benson
  • uploads///becdaabdacaceddd
    Earnings Report

    Johnson & Johnson Stock Remained Neutral to 2Q15 Earnings

    Due to the decelerating revenue growth over all segments, Johnson & Johnson (JNJ) reported a decrease in its top line by ~8.8% in its 2Q15 earnings release on July 14, 2015.

    By Mike Benson
  • uploads///Chart  Other
    Earnings Report

    A Look at Bristol-Myers Squibb’s Other Segments in 1Q17

    Bristol-Myers Squibb’s (BMY) other segments include the Neuroscience segment, the Cardiovascular segment, and the Immuno-Science segment.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Pfizer’s Growth Rate and Estimates

    Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.

    By Mike Benson
  • uploads///hands _
    Healthcare

    Novartis Enters Agreement to Acquire AveXis

    On April 9, 2018, Novartis AG announced that it had entered into an agreement to acquire AveXis for ~$8.7 billion.

    By Mike Benson
  • uploads///thermometer _
    Earnings Report

    Eli Lilly and Co.’s Strong Q1 Results, Updated 2018 Guidance

    Eli Lilly and Co. reported revenues of ~$5.7 billion for 1Q18 today, reflecting 9% growth from 1Q17.

    By Mike Benson
  • uploads///herb _
    Company & Industry Overviews

    Curaleaf Opens Medical Marijuana Dispensary in Tallahassee

    On November 16, Curaleaf Holdings announced that the company opened Tallahassee’s largest medical marijuana dispensary.

    By Mike Benson
  • uploads///joshua coleman  unsplash
    Earnings Report

    Sanofi Misses Wall Street Estimates for 1Q18 Revenues

    Sanofi (SNY) missed Wall Street analysts’ estimates for revenues today but beat estimates for earnings per share.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What to Expect from Johnson & Johnson’s 4Q15 Earnings

    Johnson & Johnson has returned nearly 1.2% year-to-date while Sanofi, Merck, and Novartis have returned ~0.5%, -4.4%, and -3.5%, respectively.

    By Mike Benson
  • uploads///Chart  Rev EPS
    Company & Industry Overviews

    What’s Gilead Sciences’ Valuation?

    Gilead’s stock price has risen ~8.9% in the last 12 months. Wall Street analysts estimate that the stock price will fall ~4.5% over the next 12 months.

    By Mike Benson
  • uploads///Oncology
    Earnings Report

    AstraZeneca’s Oncology Segment: How Did It Perform in 2Q15?

    AstraZeneca’s oncology segment is another key focus area. The segment contributed 11.6% in 2014 and 12.1% in 2Q15. Key products for oncology are Zoladex and Faslodex.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Analyzing Johnson & Johnson’s Segment-Wise Performance in 1Q18

    Johnson & Johnson reported growth across all three of its segments: the pharmaceutical segment, the consumer health segment, and the medical devices segment.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Merial Contributes to Sanofi’s Growth

    Merial, Sanofi’s (SNY) Animal Health segment, reported total revenues of 725 million euros (about $818.6 million), which is a 9.1% increase over 2Q15.

    By Mike Benson
  • uploads///Chart  EPS
    Miscellaneous

    Understanding Allergan’s Valuation after the 1Q17 Results

    On May 10, 2017, Allergan (AGN) was trading at a forward PE multiple of ~14.1x, as compared to the industry average of 11.9x.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca’s Key Focus: Oncology

    AstraZeneca’s (AZN) key focus is its oncology segment. The segment’s contribution increased to more than 12% in 1Q16. Its key products include Zoladex, Faslodex, and Iressa.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Other Drugs for Non-small Cell Lung Cancer

    Approximately 85% of all lung cancers in the United States are non-small cell lung cancers, and 10% to 15% of these are EGFR mutation-positive.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Novartis’s 3Q16 Estimates: Innovative Medicines Segment

    Novartis’s Innovative Medicines segment, formerly referred to as the Pharmaceutical segment, consists of products for a variety of therapeutic areas.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Pfizer’s Products with Declining Revenues in Q1 2018

    Enbrel, Pfizer’s (PFE) blockbuster drug, reported a 14% decline to $506 million in the first quarter.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Novartis’s 4Q16 Estimates: Innovative Medicines Segment

    The overall contribution of the Innovative Medicines segment is ~67% of Novartis’s total revenues.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Oncology Segment: Another Growth Platform for AstraZeneca?

    The oncology segment is another key focus area of AstraZeneca (AZN). The oncology segment’s contribution increased from ~11.6% in 2014 to ~12.1% in 2015.

    By Mike Benson
  • uploads///hospital _
    Earnings Report

    Allergan’s 1Q18 Earnings: Analysts’ Estimates

    Allergan (AGN) plans to release its 1Q18 earnings on April 30. Wall Street expect AGN’s earnings per share to reach $3.36.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    Merck’s Relebactam Met Primary Endpoints in Phase 3 Study

    Merck’s Relebactam is an investigational drug for the treatment of certain forms of imipenem-non-susceptible bacterial infections.

    By Mike Benson
  • uploads///virus _
    Earnings Report

    Bristol-Myers Squibb’s 1Q18 Earnings Beat Wall Street Estimates

    Bristol-Myers Squibb beat Wall Street analysts’ estimates for earnings per share and revenues in 1Q18.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Eli Lilly’s 1Q18 Earnings: Cardiovascular Products Portfolio

    Eli Lilly’s (LLY) Human Pharmaceuticals business includes cardiovascular products Effient, Cialis, and Adcirca, which reported lower sales in 1Q18.

    By Mike Benson
  • uploads///Chart
    Miscellaneous

    Teva’s Respiratory Drugs Contribute 11% to Specialty Medicines

    Teva’s respiratory drugs franchise provides solutions for asthma, COPD, and allergic rhinitis. Respiratory drugs contributed nearly 11% of total revenues for Teva’s Specialty Medicines in 2014.

    By Mike Benson
  • uploads///Chart  NVO
    Miscellaneous

    Performance of Novo Nordisk Stock in 2Q17

    Novo Nordisk (NVO) stock has risen ~18.6% in 2Q17. It has risen ~16.9% year-to-date as of July 7, 2017.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    Pfizer Reports 1Q18 Earnings and Revenue Growth

    Pfizer (PFE) released its 1Q18 earnings today, reporting another strong quarter for the Innovative health business.

    By Mike Benson
  • uploads///chart_ __ _cresemba
    Company & Industry Overviews

    Pfizer Has Received Commercial Rights for Cresemba in Europe

    On June 14, 2017, Pfizer (PFE) announced an agreement with Basilea Pharmaceutica for exclusive commercial rights for Cresemba in Europe.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Bristol-Myers Squibb: What Do Its Other Segments Offer?

    Bristol-Myers Squibb’s (BMY) neuroscience segment’s sales declined by 63.0% in 2015 from 2014, while its immunoscience segment’s sales improved ~14.1%.

    By Mike Benson
  • uploads///checklist _
    Healthcare

    Major M&A Deals in Pharmaceutical Sector in May and June

    On June 1, GlaxoSmithKline (GSK) completed the buyout of a 36.5% stake in Novartis (NVS) in a consumer healthcare joint venture.

    By Mike Benson
  • uploads///Animal Health Segment
    Earnings Report

    How Did Merial Contribute to Sanofi’s 2Q15 Growth?

    Merial reported total revenues of 691 million euros, a 14.2% increase at constant exchange rates over 2Q14.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Analysts’ Recommendations for GlaxoSmithKline in May

    GSK reported EPS of 24.60 British pence on revenue of 7.22 billion pounds, surpassing Wall Street analysts’ consensus estimates.

    By Mike Benson
  • uploads///Article
    Company & Industry Overviews

    Understanding Johnson & Johnson’s Ownership Structure

    As of January 2015, Johnson & Johnson’s ownership structure is dominated by passive investments. They account for more than 80% of the total ownership structure.

    By Mike Benson
  • uploads///people _
    Financials

    Why Envision Healthcare Stock Rose ~2.4% Last Week

    Healthcare service provider Envision Healthcare (EVHC) announced its agreement to be acquired by KKR (KKR) last week.

    By Mike Benson
  • uploads///chemist _
    Healthcare

    Why Sesen Bio Stock Jumped Over 37% this Week

    Sesen Bio (SESN), formerly known as Eleven Biotherapeutics, is developing next-generation antibody-drug conjugate therapies. The stock jumped ~26.1% to $2.27 yesterday.

    By Mike Benson
  • uploads///jaron nix  unsplash
    Company & Industry Overviews

    Pfizer’s Valuation as of May 22

    Pfizer trades at a forward enterprise-value-to-EBITDA multiple of 10.3x, which is much lower than the industry average of 11.6x.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Why Eli Lilly Expects 2Q17 Revenue Growth

    As per analysts’ estimates, Eli Lilly’s (LLY) revenues could rise ~3.6% to $5.6 billion in 2Q17.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Inside Novartis’s Eye Care Performance in 4Q16

    Alcon, NVS’s eye care segment, saw its 4Q16 revenues fall ~2% to ~$1.4 billion, including no change in sales but a -2% impact from foreign exchange.

    By Mike Benson
  • uploads///Chart  Ph
    Company & Industry Overviews

    Why GlaxoSmithKline’s Pharmaceuticals Business Grew

    GlaxoSmithKline is a major shareholder of ViiV Healthcare. Its HIV products reported revenue of 1.12 billion pounds during 2Q17.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Eli Lilly’s Cardiovascular Products Have Been Faring

    Eli Lilly and Company’s (LLY) Human Pharmaceutical segment includes cardiovascular products such as Cialis, Effient, and other products.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What Analysts Expect from Pfizer in the Years to Come

    Due to Pfizer’s (PFE) strong Innovative Products business and product pipeline, analysts estimate that it will generate $0.54 in earnings per share in 1Q16.

    By Mike Benson
  • uploads///Costs
    Earnings Report

    Johnson & Johnson’s Profitability Improves in 2Q15

    Johnson & Johnson’s net profit margin improved to 25.4% for 2Q15 compared to 22.2% for 2Q14 due to the divestiture of some low profitability products and improved sales of high profitability products.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How AstraZeneca’s Oncology Products Performed in 4Q17

    AstraZeneca’s (AZN) oncology products include legacy oncology products as well as new oncology products.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What Are Analysts Estimating for Allergan Today?

    AGN’s analysts estimate EPS of $4.72 on revenues of $4.27 billion for 4Q17, which would be 10.5% higher YoY (year-over-year).

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Sanofi’s Consumer Healthcare and Generics Franchises

    Sanofi’s (SNY) Consumer Healthcare franchise’s products include Allegra, Doliprane, and Nasacort. The segment reported a 3.1% decline in revenues at 905 million euros in 1Q16, compared to its 1Q15 revenues.

    By Mike Benson
  • uploads///Article
    Earnings Report

    Why Novartis’s Revenues Declined Marginally

    In 2Q15, Novartis (NVS) achieved revenues of $12.69 billion, an increase of ~6.3% over 1Q15.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Behind Bristol-Myers Squibb’s Continued Growth in 1Q16

    Bristol-Myers Squibb (BMY) reported a growth of 9% in 1Q16. Analyst estimates forecast a high-single-digit growth to low-double-digit in revenues in 2016.

    By Mike Benson
  • uploads///microscope _
    Earnings Report

    BeiGene’s Q2 2018 Earnings: Reports Revenue Growth

    BeiGene (BGNE) released its Q2 2018 earnings on August 9. BGNE surpassed analysts’ estimates for revenues but missed its EPS estimates.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Performance of Cannabis Stocks in Week 48

    In this article, we’ll discuss the performances of a few stocks from the cannabis industry (SEED) for the week that ended on November 30.

    By Mike Benson
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.